Search results for "coronary"

showing 10 items of 1588 documents

Glycogen phosphorylase BB in acute coronary syndromes

2005

AbstractThe diagnosis of myocardial damage is preferably based on measurement of the cardiac-specific troponins. However, there is an emerging need for early, specific cardiac markers. One potential candidate is the glycogen phosphorylase BB isoenzyme (GPBB). We investigated the use of a new, commercially available GPBB ELISA assay in 61 patients presenting with an acute coronary syndrome (37 acute myocardial infarction, 24 unstable angina pectoris) in comparison to established cardiac markers such as troponin T, creatine kinase isoenzyme MB (CKMB) mass, and myoglobin. Blood samples were obtained on arrival, as well as 1, 2, 3, 4, 8, 12 and 24h later. GPBB plasma concentrations were elevate…

AdultMalemedicine.medical_specialtyAcute coronary syndromeTime FactorsClinical BiochemistryMyocardial InfarctionCoronary DiseaseEnzyme-Linked Immunosorbent AssayGlycogen phosphorylase isoenzyme BBChest painSensitivity and SpecificityAngina PectorisAnginaTroponin TInternal medicinemedicineCreatine Kinase MB FormHumansPhosphorylase bMyocardial infarctionTroponin TbiologyMyoglobinUnstable anginabusiness.industryBiochemistry (medical)General MedicineMiddle Agedmedicine.diseaseTroponinIsoenzymesAcute DiseaseCardiologybiology.proteinmedicine.symptombusinessBiomarkersClinical Chemistry and Laboratory Medicine (CCLM)
researchProduct

Copeptin Improves Early Diagnosis of Acute Myocardial Infarction

2010

ObjectivesEarly identification of myocardial infarction in chest pain patients is crucial to identify patients at risk and to maintain a fast treatment initiation.BackgroundThe aim of the current investigation is to test whether determination of copeptin, an indirect marker for arginin-vasopressin, adds diagnostic information to cardiac troponin in early evaluation of patients with suspected myocardial infarction.MethodsBetween January 2007 and July 2008, patients with suspected acute coronary syndrome were consecutively enrolled in this multicenter study. Copeptin, troponin T (TnT), myoglobin, and creatine kinase-myocardial band were determined at admission and after 3 and 6 h.ResultsOf 1,…

AdultMalemedicine.medical_specialtyAcute coronary syndromechest paindiagnosisMyocardial InfarctionChest painAngina PectorisCopeptinTroponin TPredictive Value of TestsInternal medicinemedicineHumansMyocardial infarctionProspective StudiesAgedTroponin TtroponinUnstable anginabusiness.industryMyoglobinTroponin IGlycopeptidescopeptinMiddle Agedmedicine.diseaseEarly DiagnosisCardiologyMyocardial infarction complicationsFemaleMyocardial infarction diagnosismedicine.symptombusinessCardiology and Cardiovascular MedicineBiomarkersJournal of the American College of Cardiology
researchProduct

Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELT…

2016

AIMS Our aim was to compare, in a large unprotected left main coronary artery (ULMCA) all-comer registry, the long-term clinical outcome after percutaneous coronary intervention (PCI) with first-generation drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) in patients with acute coronary syndrome (ACS). METHODS AND RESULTS Of a total of 2,775 patients enrolled in the Drug Eluting Stents for Left Main Coronary Artery Disease (DELTA) multicentre registry, 379 (13.7%) patients with ACS treated with PCI (n=272) or CABG (n=107) were analysed. Baseline demographics were considerably different in the two groups before propensity matching. No significant differences emerged for…

AdultMalemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineInternal medicineHumansMedicineRegistriescardiovascular diseases030212 general & internal medicineMyocardial infarctionAcute Coronary SyndromeCoronary Artery BypassStrokeAgedAged 80 and overbusiness.industryIncidence (epidemiology)Coronary StenosisPercutaneous coronary interventionDrug-Eluting StentsMiddle Agedmedicine.diseaseSurgeryStrokeTreatment Outcomemedicine.anatomical_structurePropensity score matchingConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessArteryEuroIntervention
researchProduct

Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic scler…

2017

Objective To evaluate occult cardiac involvement in asymptomatic systemic sclerosis (SSc) patients by pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance (CMR), for a very early identification of patients at higher risk of cardiac-related mortality. Methods Sixteen consecutive patients with definite SSc, fulfilling the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria in less than 1 year from the onset of Raynaud's phenomenon, underwent pharmacological stress, rest perfusion and delayed enhancement CMR. At enrollment, no patient showed signs and/or symptoms suggestive for cardiac involvement. No patient sho…

AdultMalemedicine.medical_specialtyAdenosineHeart diseaseHeart DiseasesVasodilator AgentsContrast MediaMagnetic Resonance Imaging CineAsymptomaticCardiac magnetic resonance imaging with pharmacological stress; Myocardial perfusion defect; Systemic sclerosis; Systemic sclerosis heart involvement; Rheumatology030218 nuclear medicine & medical imaging03 medical and health sciencesMyocardial perfusion imagingCoronary circulation0302 clinical medicineRheumatologyPredictive Value of TestsInternal medicineCoronary CirculationCardiac magnetic resonance imaging with pharmacological stressMultidetector Computed TomographymedicineHumans030203 arthritis & rheumatologyScleroderma Systemicmedicine.diagnostic_testbusiness.industryMicrocirculationMyocardial Perfusion Imagingmedicine.diseaseRheumatologymyocardial perfusion defectSettore MED/16 - Reumatologiamedicine.anatomical_structureEarly DiagnosisVentriclecardiac magnetic resonance imaging with pharmacological streAsymptomatic Diseasessystemic sclerosis heart involvementSystemic sclerosisFemaleRadiologymedicine.symptombusinessPerfusionsystemic sclerosiRheumatism
researchProduct

Effectiveness of cascade filtration plasmapheresis in two patients affected by familial hypercholesterolemia

1995

Hypercholesterolemia has been recognised as a primary risk factor for coronary heart disease. Reduction of plasma levels of total and LDL cholesterol has been shown to decrease coronary atherosclerosis. Plasmapheresis represents an useful non-pharmacological tool to treat severe hypercholesterolemias. We have evaluated the effectiveness of a system of plasmapheresis using a cascade filtration method in two young male subjects (aged 16 and 26 years) with homozygous familial hypercholesterolemia. Both showed severe coronary atherosclerosis as determined by angiography. Procedures were performed at intervals of 7 days in each case. We observed a mean reduction of plasma levels of total cholest…

AdultMalemedicine.medical_specialtyAdolescentApolipoprotein Bmedicine.medical_treatmentFamilial hypercholesterolemiaFibrinogenGastroenterologyHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicinemedicineHumansHyperlipoproteinemia Type IIRisk factorCoronary atherosclerosisbiologybusiness.industryCholesterolCholesterol LDLPlasmapheresisHematologyGeneral Medicinemedicine.diseaseEndocrinologychemistrybiology.proteinlipids (amino acids peptides and proteins)PlasmapheresisbusinessFiltrationmedicine.drugJournal of Clinical Apheresis
researchProduct

Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-media…

2011

Dalcetrapib increases high-density lipoprotein cholesterol (HDL-C) levels through effects on cholesteryl ester transfer protein (CETP). As part of the dalcetrapib dal-HEART clinical trial programme, the efficacy and safety of dalcetrapib is assessed in coronary heart disease (CHD) patients in the dal-VESSEL study (ClinicalTrials.gov identifier: NCT00655538), the design and methods of which are presented here. RESEARCH DESIGN AND STUDY METHOD: Men and women with CHD or CHD risk equivalent, with HDL-C levels50  mg/dL were recruited for a 36-week, double-blinded, placebo-controlled trial. After a pre-randomisation phase of up to 8 weeks, patients received dalcetrapib 600  mg/day or placebo in …

AdultMalemedicine.medical_specialtyAdolescentBrachial ArteryDalcetrapibCoronary DiseaseAtherosclerosis CETP inhibition Endothelial function Flow-mediated dilatation ester transfer protein density-lipoprotein cholesterol off-target toxicity cardiovascular-disease dependent vasodilation coronary risk nitric-oxide torcetrapib atherosclerosis cetpModels BiologicalPlaceboschemistry.chemical_compoundYoung AdultDouble-Blind Methodmedicine.arteryInternal medicineCholesterylester transfer proteinmedicineHumansSulfhydryl CompoundsBrachial arteryLipoprotein cholesterolFlow mediated vasodilatationAgedRationalizationbiologybusiness.industryAnticholesteremic AgentsEstersGeneral MedicineCetp inhibitionMiddle AgedAmidesCoronary heart diseaseClinical trialVasodilationTreatment OutcomechemistryRegional Blood FlowResearch DesignCardiologybiology.proteinlipids (amino acids peptides and proteins)FemaleEndothelium VascularbusinessAlgorithms
researchProduct

Long-term effects of a multidisciplinary treatment of uncomplicated obesity on carotid intima-media thickness

2011

Obesity is associated with well-known cardiovascular risk factors and a lower life expectancy. This study investigated whether nonoperative nutritional treatment of obesity without comorbidities influenced the carotid intima-media thickness (c-IMT) in the long run. Fifty-four subjects of an original cohort of 251 subjects were re-evaluated 10 years after a medical nutritional treatment (MNT) with cognitive-behavioral approach for uncomplicated obesity. Forty subjects were classified as failure (10-year body weight change >0.5 kg) and 14 (body weight change ≤0.5 kg) as a success of the MNT. Ten years after MNT, c-IMT significantly increased (0.06 ± 0.02 mm; P = 0.004) in the failure group an…

AdultMalemedicine.medical_specialtyAdolescentDiet ReducingCarotid Artery CommonEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Coronary Artery DiseaseWeight GainSeverity of Illness IndexBody Mass IndexCohort StudiesYoung AdultEndocrinologyBehavior TherapyRisk FactorsInternal medicineSeverity of illnessmedicineHumansSingle-Blind MethodObesityAgedNutrition and Dieteticsbusiness.industryAge FactorsMiddle AgedStepwise regressionmedicine.diseaseObesitySurgeryItalyIntima-media thicknessobesity treatment carotid intima-media thicknessCohortFemalemedicine.symptomTunica IntimaTunica MediabusinessWeight gainBody mass indexFollow-Up StudiesCohort study
researchProduct

Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management

2011

The mucopolysaccharidoses (MPSs) are inherited lysosomal storage disorders caused by the absence of functional enzymes that contribute to the degradation of glycosaminoglycans (GAGs). The progressive systemic deposition of GAGs results in multi-organ system dysfunction that varies with the particular GAG deposited and the specific enzyme mutation(s) present. Cardiac involvement has been reported in all MPS syndromes and is a common and early feature, particularly for those with MPS I, II, and VI. Cardiac valve thickening, dysfunction (more severe for left-sided than for right-sided valves), and hypertrophy are commonly present; conduction abnormalities, coronary artery and other vascular in…

AdultMalemedicine.medical_specialtyAdolescentMucopolysaccharidosisClinical SciencesHeart Valve DiseasesReviewComorbidityCoronary Artery DiseaseDiseaseMuscle hypertrophyCoronary artery diseaseElectrocardiographyVentricular hypertrophyTachycardiaInternal medicineGeneticsmedicineHumansGenetics(clinical)Age of OnsetSinusChildPreschoolGenetics (clinical)GlycosaminoglycansGenetics & Hereditymedicine.diagnostic_testbusiness.industryMitral Valve InsufficiencyHypertrophyAortic Valve StenosisEnzyme replacement therapyMucopolysaccharidosesMiddle Agedmedicine.diseaseLeft VentricularCausalityTachycardia SinusEchocardiographyChild PreschoolAortic valve stenosisCardiologyHypertrophy Left VentricularFemalebusinessElectrocardiographyJournal of Inherited Metabolic Disease
researchProduct

Fragment reconstruction of coronary arteries using transesophageal echocardiography for coronary diagnostics

2008

Aims Ultrasound differs procedurally from the established methods for non-invasive coronary visualization and is therefore an interesting alternative for non-invasive diagnostics. In this study, fragment reconstruction of coronary arteries by transesophageal echocardiography (FRC-TEE) was investigated for the first time in a patient population being evaluated for coronary angiography. Methods and results Ultrasonic and angiographic findings were compared visually and using quantitative measurements in 50 patients. One hundred and seventy-one vessels were examined by FRC-TEE. The total lengths visualized were 9.6+ 1.7 cm for the right coronary artery, 7.0+ 1.1 cm for left circumflex, 3.9+ 1.…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentCoronary Artery DiseaseCoronary AngiographySensitivity and SpecificitySampling StudiesCoronary artery diseaseGermanyInternal medicinemedicine.arteryImage Processing Computer-AssistedmedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesCircumflexAgedAged 80 and overmedicine.diagnostic_testbusiness.industryCoronary StenosisStentGeneral MedicineMiddle Agedmedicine.diseaseCoronary VesselsCoronary arteriesStenosismedicine.anatomical_structureRight coronary arteryAngiographyCardiologyFemaleCardiology and Cardiovascular Medicinebusinesshuman activitiesEchocardiography Transesophagealcirculatory and respiratory physiologyArteryEuropean Journal of Echocardiography
researchProduct

Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but with…

1997

To evaluate the behavior of cardiac arrhythmias (CA) and transient episodes of myocardial ischemia (TEMI), in relation to the circadian pattern of blood pressure in patients suffering from arterial hypertension, with or without echocardiographically ascertained left ventricular hypertrophy (LVH), we studied 128 patients, 87 men (M) and 41 women (F), aging from 21 to 76 years, subdivided into two groups: Group I, including 66 patients with LVH (45 M and 21 F; mean age of 53.7 ± 9.1 years; Group II, including 62 patients without LVH ( 42 M and 20 F; mean age of 49.7 ± 9.5 years). Office blood pressure (OBP) as well as nighttime ambulatory blood pressure (ABP) were higher in patients with LVH …

AdultMalemedicine.medical_specialtyAmbulatory blood pressureHeart diseasePremature atrial contractionMyocardial IschemiaBlood PressureCoronary DiseaseVentricular tachycardiaLeft ventricular hypertrophyElectrocardiographyHeart RateInternal medicineHeart rateInternal MedicinemedicineHumanscardiovascular diseasesAgedbusiness.industryArrhythmias CardiacBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseEchocardiography DopplerCircadian RhythmBlood pressureHypertensioncardiovascular systemCardiologyFemaleHypertrophy Left VentricularSupraventricular tachycardiabusinessAmerican journal of hypertension
researchProduct